跳至主要内容
临床试验/NCT04658134
NCT04658134Unknown不适用

Glycine "Deficiency" and the Kinetics of Acylglycine in Morbid Obesity

Singapore General Hospital1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2021年1月20日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
20
试验地点
1
主要终点
Acylglycine concentration

研究概览

简要总结

This study aims to evaluate the effects of oral glycine supplementation on plasma glycine concentration, intracellular glutathione (GSH) concentration, plasma acylglycine concentration, urine acylglycine concentration, and insulin resistance in subjects with morbid obesity.

This is an open-labelled trial. 20 adults with morbid obesity will be recruited. Following screening and baseline metabolic evaluations, eligible subjects will be given oral glycine supplements for 14 ± 5 days. Upon completing glycine supplementation, subjects will return for their post-supplement metabolic assessment.

The investigators hypothesize that oral glycine supplementation in morbidly obese patients normalizes plasma glycine concentration, increases intracellular GSH concentration, increases plasma and urinary acylglycine concentration, and improves insulin resistance.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
21 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age: 21-65 years
  • •BMI ≥ 32.5 kg/m2
  • •Able to provide informed consent
  • •Able to maintain present diet throughout the study duration

排除标准

  • •Weight > 150 kg
  • •Type 2 Diabetes Mellitus
  • •Allergy to soy
  • •Ongoing treatment with weight-loss medications (e.g. orlistat, phentermine, liraglutide)
  • •Systemic steroid usage (eg. prednisolone, hydrocortisone, cortisone, dexamethasone)
  • •Renal impairment (estimated creatinine clearance estimated by Cockcroft-Gault Equation < 60 ml/min)
  • •Haemoglobin concentration < 10 g/L
  • •Serum alanine aminotransferase or aspartate aminotransferase above 2x upper limit of normal
  • •Uncontrolled hypertension (BP > 180/110 mmHg)
  • •Nursing mothers
  • •Uncontrolled thyroid disease
  • •Surgery requiring general anaesthesia within 4-weeks before enrolment
  • •Psychiatric disorders requiring medication
  • •Significant alcohol intake (> 1 unit per day for women and > 2 units per day for men)
  • •Cancer within the last 3-years (except squamous cell and basal cell cancer of the skin)
  • •Any factors likely to limit adherence to study protocol

研究组 & 干预措施

Glycine supplementation

Experimental

Glycine supplementation

干预措施: Glycine (Dietary Supplement)

结局指标

主要结局

Acylglycine concentration

时间窗: 14 days

Post-treatment changes acylglycine concentration in plasma and urine

Acylcarnitine concentration

时间窗: 14 days

Post-treatment changes acylcarnitine concentration in plasma and urine

Amino acid concentration

时间窗: 14 days

Post-treatment changes amino acid concentration in plasma and red blood cell

Glutathione concentration

时间窗: 14 days

Post-treatment changes in glutathione concentration in plasma and red blood cell

次要结局

  • Insulin resistance index(14 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验